Related references
Note: Only part of the references are listed.Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies
M. Borte et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Update on the use of immunoglobulin in human disease: A review of evidence
Elena E. Perez et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis
Hosein Shabaninejad et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2016)
Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America
Daniel Suez et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2016)
Efficacy and tolerability of 16% subcutaneous immunoglobulin compared with 20% subcutaneous immunoglobulin in primary antibody deficiency
H. B. Niebur et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Practice parameter for the diagnosis and management of primary immunodeficiency
Francisco A. Bonilla et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease
Stephen Jolles et al.
CLINICAL IMMUNOLOGY (2014)
Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies
Richard L. Wasserman
IMMUNOTHERAPY (2014)
SCIg vs IVIg: Let's Give Patients the Choice!
K. Samaan et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2014)
Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency Diseases
Hirokazu Kanegane et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2014)
Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment
Teresa Espanol et al.
Patient Preference and Adherence (2014)
Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again
Richard L. Wasserman
JOURNAL OF CLINICAL IMMUNOLOGY (2012)
Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy
S. Jolles et al.
CLINICAL IMMUNOLOGY (2011)
Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose
Melvin Berger
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease
Richard L. Wasserman et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Efficacy and Safety of Hizentra®, a New 20% Immunoglobulin Preparation for Subcutaneous Administration, in Pediatric Patients with Primary Immunodeficiency
Michael Borte et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2011)
Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency
John B. Hagan et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies -: A prospective, multi-national study
Ann Gardulf et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2006)
Share Paper
